Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Steven T. Rosen"'
Autor:
Aliyah R. Sohani, Joycelynne Palmer, Alex F. Herrera, Yi-Bin Chen, Lihua E. Budde, Philippe Armand, Stephen J. Forman, Robert J. Soiffer, Christine Pak, Dennis D. Weisenburger, Amrita Krishnan, Jasmine Zain, Tanya Siddiqi, Wing C. Chan, Leslie Popplewell, Joseph H. Antin, Robert T. Chen, Liana Nikolaenko, John Koreth, Sarah Nikiforow, Dongyun Yang, Scott J. Rodig, German Pihan, Joyce Murata-Collins, Joo Y. Song, Matthew Mei, Larry W. Kwak, David M. Weinstock, Victoria Bedell, Corey Cutler, Auayporn Nademanee, Paola Dal Cin, Young L. Kim, Steven T. Rosen, Vincent T. Ho, Gabriel K. Griffin, Edwin P. Alyea, Raju Pillai
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:514-520
Double-hit lymphomas (DHLs) and double-expressor lymphomas (DELs) are associated with resistance to frontline and salvage immunochemotherapy, as well as autologous stem cell transplantation (SCT). We hypothesized that allogeneic SCT (alloSCT) could o
Autor:
Steven M. Horwitz, Barbara Pro, Francine M. Foss, Lauren C. Pinter-Brown, Eric D. Hsi, Mary Jo Lechowicz, Anil Tulpule, Carla Casulo, Sonali M. Smith, Frederick Lansigan, Tatyana Feldman, Lisa A. Bellm, Ranjana H. Advani, Michael Craig, Mark Acosta, Christian Gisselbrecht, Andrei R. Shustov, John P. Greer, Brad S. Kahl, Steven T. Rosen, Neil Morganstein, Marc Schwartz, Kenneth R. Carson, Steven I. Park, Joseph W. Leach, Massimo Federico
Publikováno v:
Cancer. 123:1174-1183
BACKGROUND Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, and there currently is no clear consensus regarding the initial therapy used for these diseases. Herein, the authors analyzed treatment pat
Autor:
Joan Guitart, Madeleine Duvic, Christiane Querfeld, Steven T. Rosen, Timothy M. Kuzel, Stephen W. Dusza, Youn H. Kim
Publikováno v:
Blood. 123:1159-1166
A phase 2 multicenter trial was performed to evaluate single-agent lenalidomide in advanced, refractory mycosis fungoides/Sézary syndrome. Thirty-two patients were enrolled with a median of 6 prior treatment regimens, including a median of 4 systemi
Autor:
Michael Y. Choi, Constantine S. Tam, Danielle M. Brander, Ming Zhu, Mary Ann Anderson, Jacqueline C. Barrientos, John F. Seymour, Elisa Cerri, Monali Desai, Shuo Ma, Wijith Munasinghe, Andrew W. Roberts, Rod A. Humerickhouse, Gary Gordon, Maria Verdugo, Thomas J. Kipps, Leanne Lash, Matthew S. Davids, Steven T. Rosen, Su Young Kim, Suresh Agarwal, Betty Prine, Anne W. Beaven
Publikováno v:
The Lancet. Oncology, vol 18, iss 2
Summary Background Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this s
Autor:
Steven T. Rosen, Annette Larsen, Jennifer C Colvin, Justin Kline, Jane N. Winter, Sonali M. Smith, Leo I. Gordon, Koen M. Van Besien, Irene Helenowski, Andrew M. Evens
Publikováno v:
British Journal of Haematology. 163:55-61
There remains an unmet therapeutic need for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL). We conducted a phase I/II trial with bortezomib (dose-escalated to 1·6 mg/m(2) ) given concurr
Publikováno v:
Current Treatment Options in Oncology. 13:102-121
Treatment regimens of patients with CTCL vary widely based on clinician preference and patient tolerance. Skin directed therapies are recommended for patients with early stage IA and IB MF, with combinations used in refractory cases. While no regimen
Autor:
Alfred Rademaker, Christiane Querfeld, Joan Guitart, Neha S. Mehta, Timothy M. Kuzel, Steven T. Rosen, Pedram Gerami
Publikováno v:
Leukemia & Lymphoma. 50:1969-1976
We present the results of an open-label clinical trial and the clinical use of alemtuzumab in 19 heavily pretreated patients with advanced erythrodermic cutaneous T-cell lymphomas (CTCL) (erythrodermic mycosis fungoides and Sézary syndrome). Ten pat
Autor:
Joan Guitart, Timothy M. Kuzel, Michelle S. Gentile, Steven T. Rosen, Maria Estela Martinez-Escala, Tarita O. Thomas, Bharat B. Mittal
Publikováno v:
BioMed Research International, Vol 2015 (2015)
BioMed Research International
BioMed Research International
Objectives. CD30+lymphoproliferative disorder is a rare variant of cutaneous T-cell lymphoma. Sustained complete response following first-line treatments is rare. This retrospective review evaluates the response of refractory or recurrent lesions to
Autor:
Katharine A. Kirby, Christiane Querfeld, Joan Guitart, Bettina M. Prinz, Henry H. Roenigk, Timothy M. Kuzel, Steven T. Rosen
Publikováno v:
Archives of Dermatology. 141:305-311
Objectives To evaluate long-term outcomes, impact of maintenance therapy and potential curability of patients with mycosis fungoides (MF) treated with psoralen plus UV-A (PUVA) monotherapy. Design Single-center retrospective cohort analysis. Setting
Publikováno v:
Hematology/Oncology Clinics of North America. 17:1475-1483
Although most patients who have cutaneous T-cell lymphoma have an indolent clinical course, patients who have cutaneous tumors, lymph node or visceral involvement, or peripheral blood involvement generally have rapidly progressive disease with shorte